Literature DB >> 31045749

Do chronic pain and comorbidities affect brain function in sickle cell patients? A systematic review of neuroimaging and treatment approaches.

Joyce T Da Silva1,2, Janelle E Letzen2, Jennifer A Haythornthwaite2, Patrick H Finan2, Claudia M Campbell2, David A Seminowicz1.   

Abstract

Sickle cell disease (SCD) is a medical condition in which chronic pain is common and negatively impacts psychosocial function and quality of life. Although the brain mechanisms underlying chronic pain are well studied in other painful conditions, the brain mechanisms underlying chronic pain and the associated psychosocial comorbidities are not well established in SCD. A growing literature demonstrates the effect of treatment of chronic pain, including pharmacological and nonpharmacological treatments, on brain function. The present systematic review aimed to (1) determine the effects of chronic pain and psychosocial comorbidities on brain function of patients with SCD; (2) summarize pharmacological and nonpharmacological approaches to treat these symptoms; and (3) identify areas for further investigation of potential beneficial effects of treatments on brain function. Titles were screened using predefined criteria, including SCD, and abstracts and full texts were reviewed by 2 independent reviewers. A total of 1167 SCD articles were identified, and 86 full articles were included covering 3 sections: chronic pain (4 studies), psychosocial comorbidities (11 studies), and pharmacological and nonpharmacological treatments (71 studies). Neuroimaging evidence demonstrates aberrant neural processing related to chronic pain and psychosocial comorbidities in SCD beyond ischemic stroke and cerebral hemorrhage. Although neuroimaging studies show an important role for psychological factors, pain management is nearly exclusively based on opioids. Behavior therapy seems useful to improve psychological symptoms as well as chronic pain and quality of life. Further investigation is required with larger cohorts, matched controls, and examination of treatment-related neural mechanisms.

Entities:  

Mesh:

Year:  2019        PMID: 31045749      PMCID: PMC6699910          DOI: 10.1097/j.pain.0000000000001591

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  141 in total

Review 1.  Salience processing and insular cortical function and dysfunction.

Authors:  Lucina Q Uddin
Journal:  Nat Rev Neurosci       Date:  2014-11-19       Impact factor: 34.870

2.  Original research: using guided imagery to manage pain in young children with sickle cell disease.

Authors:  Cassandra Elaine Dobson; Mary Woods Byrne
Journal:  Am J Nurs       Date:  2014-04       Impact factor: 2.220

3.  Comprehensive, integrative management of pain for patients with sickle-cell disease.

Authors:  Saunjoo L Yoon; Shakera Black
Journal:  J Altern Complement Med       Date:  2006-12       Impact factor: 2.579

4.  The effects of comprehensive guidelines for the care of sickle-cell patients in crisis on the nurses' knowledge base and job satisfaction for care given.

Authors:  E A Lorenzi
Journal:  J Adv Nurs       Date:  1993-12       Impact factor: 3.187

5.  White matter integrity and core cognitive function in children diagnosed with sickle cell disease.

Authors:  Nadia Scantlebury; Donald Mabbott; Laura Janzen; Conrad Rockel; Elysa Widjaja; Garland Jones; Melanie Kirby; Isaac Odame
Journal:  J Pediatr Hematol Oncol       Date:  2011-04       Impact factor: 1.289

6.  Mechanism-driven phase I translational study of trifluoperazine in adults with sickle cell disease.

Authors:  Robert E Molokie; Diana J Wilkie; Harriett Wittert; Marie L Suarez; Yingwei Yao; Zhongsheng Zhao; Ying He; Zaijie J Wang
Journal:  Eur J Pharmacol       Date:  2013-11-07       Impact factor: 4.432

7.  IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies.

Authors:  Carlton D Dampier; Wally R Smith; Carrie G Wager; Hae-Young Kim; Margaret C Bell; Scott T Miller; Debra L Weiner; Caterina P Minniti; Lakshmanan Krishnamurti; Kenneth I Ataga; James R Eckman; Lewis L Hsu; Donna McClish; Sonja M McKinlay; Robert Molokie; Ifeyinwa Osunkwo; Kim Smith-Whitley; Marilyn J Telen
Journal:  Clin Trials       Date:  2013-04       Impact factor: 2.486

8.  Quantitative MRI of the brain in children with sickle cell disease reveals abnormalities unseen by conventional MRI.

Authors:  R G Steen; W E Reddick; R K Mulhern; J W Langston; R J Ogg; A A Bieberich; P B Kingsley; W C Wang
Journal:  J Magn Reson Imaging       Date:  1998 May-Jun       Impact factor: 4.813

9.  Consistent neuroanatomical age-related volume differences across multiple samples.

Authors:  Kristine B Walhovd; Lars T Westlye; Inge Amlien; Thomas Espeseth; Ivar Reinvang; Naftali Raz; Ingrid Agartz; David H Salat; Doug N Greve; Bruce Fischl; Anders M Dale; Anders M Fjell
Journal:  Neurobiol Aging       Date:  2009-06-30       Impact factor: 4.673

Review 10.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.